Guidance Archives - Page 32 of 637

2 minute read

Orthopedic Devices Maker Treace Medical Concepts’ Gloomy Forecast Cast Concerns Over Long-Term Viability

May 8, 3:08 PM

Treace Medical Concepts reports Q1 EPS loss of $(0.30), sales hit $51.11 million, up 21%. Surge in procedure kits sold due to expanded surgeon base and product mix shift. FY24 sales guidance adjusted to $201M-$211M. Analysts downgrade, citing competitive challenges.

TMCI

2 minute read

Why Is New York Times Stock Trading Higher On Wednesday?

By Vandana Singh

May 8, 2:56 PM

New York Times' digital subscribers hit 9.91 million, growing by 210K in Q1. Sales reached $594M, up 5.9% Y/Y. Digital ARPU rose to $9.21. CEO Meredith Kopit Levien emphasizes a strong start in 2024. Guidance predicts subscription revenues up by 6%-8% in Q2.

NYT

2 minute read

Elanco Animal Health’s Q1 Earnings Show Improved Base Business, Analyst Highlights Slightly Delayed But Encouraging Pipeline

By Vandana Singh

May 8, 2:28 PM

Elanco Animal Health (NYSE: ELAN) reports Q1 results: adjusted EPS $0.34 (-26% Y/Y), sales $1.21B (-4% Y/Y). 2024 guidance: EPS $0.88-$0.96, revenue $4.46-$4.52 billion.

ELAN

1 minute read

Perion Reports Strong Q1 Growth, Navigates New Microsoft Bing Ad Pricing Successfully

By Anusuya Lahiri

May 8, 2:08 PM

Perion Network reported Q1 2024 revenues of $157.82M, beating estimates, with increased daily searches and retail media revenue. Adjusted EPS was $0.44. Q2 revenue expected at $118M-$122M, FY2024 revenue expected at $590M-$610M.

PERI

2 minute read

What’s Going On With Ingredion Shares After Q1 Results?

By Nabaparna Bhattacharya

May 8, 2:00 PM

Ingredion shares edge up despite $51M charges from South Korean business sale, as Q1 earnings beat but revenues miss expectations.

INGR

2 minute read

Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher

By Vandana Singh

May 8, 1:49 PM

Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed across dosing groups.

TEVA

1 minute read

Gilat’s Strategic Acquisitions Fuel Growth Amid Slight Revenue Shortfall

By Anusuya Lahiri

May 8, 1:27 PM

Gilat(NASDAQ: GILT) reported Q1 2024 revenue of $76.08M, missing analyst estimate. Adjusted EPS of $0.11 beat estimate. Cash on hand was $105.1M.

GILT

2 minute read

Lion Electric’s Q1 Performance Disappoints, CEO On Streamlining Strategies To Ensure Long-Term Success

By Akanksha Bakshi

May 8, 1:23 PM

Lion Electric eports Q1 2024 revenue of $55.48M, missing consensus, with a net loss of $21.7M. The company has 2,000+ vehicles on the road.

LEV

1 minute read

Sunoco Spills the Beans: Big Beat, Higher Payout, & Brighter Outlook

By Lekha Gupta

May 8, 12:58 PM

Sunoco LP reported first-quarter FY24 results with revenues of $5.50B, exceeding consensus. Partnership increased distribution by 4% and revised FY24 guidance for adjusted EBITDA.

AMZA

2 minute read

What’s Going On With Performance Food Group Shares Wednesday?

By Nabaparna Bhattacharya

May 8, 12:46 PM

Performance Food Group reported third-quarter earnings miss reflecting difficult operating environment in the fiscal quarter.

PFGC